Science and Research

The effect of tiotropium/olodaterol versus fluticasone propionate/salmeterol on left ventricular filling and lung hyperinflation in patients with COPD

This exploratory, randomised, double-blind, double-dummy, multicentre, cross-over study explored the effect of 6 weeks of treatment with tiotropium/olodaterol (T/O) versus fluticasone propionate/salmeterol (F/S) on left ventricular filling in patients with chronic obstructive pulmonary disease with functional residual capacity (FRC) >120% predicted and postbronchodilator improvement of FRC ≥7.5%. Overall, 76 patients were randomised across nine sites. Treatment with T/O or F/S increased left ventricular end-diastolic volume index from baseline (adjusted mean change: T/O: 2.317 mL/m(2), F/S: 2.855 mL/m(2)), with no statistically significant difference between treatments. However, T/O resulted in a significantly greater reduction in lung hyperinflation versus F/S (FRC plethysmography absolute change from baseline: F/S: -0.329 L, T/O: -0.581 L).

  • Herth, F.
  • Hohlfeld, J. M.
  • Haas, J.
  • de la Hoz, A.
  • Jin, X.
  • Kreitner, K. F.
  • Vogelmeier, C.
  • Vogel-Claussen, J.
  • Watz, H.

Keywords

  • COPD pharmacology
  • inhaler devices
  • respiratory measurement
  • performed in accordance with the provisions of the Declaration of Helsinki (1996
  • version), the International Conference on Harmonisation Tripartite Guideline for
  • Good Clinical Practice, applicable regulatory requirements and Boehringer Ingelheim
  • Standard Operating Procedures. All patients provided written informed consent. This
  • article does not report individual patient data
  • all data presented here are
  • anonymised. The clinical trial protocols and the informed consent and patient
  • information forms were reviewed and received approval/favourable opinion from a
  • constituted local Institutional Review Board or an Independent Ethics Committee at
  • each centre prior to the start of the study. This study was approved by
  • Ethikkomission Medizinische Heidelberg under ID number AFmu-559/2016.
Publication details
DOI: 10.1136/bmjresp-2020-000741
Journal: BMJ Open Respir Res
Number: 1
Work Type: Review
Location: ARCN, BREATH, TLRC, UGMLC
Disease Area: COPD
Partner / Member: Ghd, ITEM, JLU, MHH, Thorax
Access-Number: 33268341

DZL Engagements

chevron-down